UPLAND, Calif.--(BUSINESS WIRE)-- #AHFcares--AHF Dedicates New Upland HIV Healthcare Center and Pharmacy

SAN FRANCISCO--(BUSINESS WIRE)--Fundamental Research Labs (FRL), the applied AI research company behind Shortcut, today announced that Brett Caughran has joined the company as Chief Growth Officer. Caughran will help to build the frontier AI stack for fundamental investors, spanning Shortcut, the leading AI agent for Excel; Sho, a long-running digital analyst; and Signals, qualitative signal development for fundamental investors. He will also lead a new Forward Deployed Investor team that embed

PRINCETON, N.J. & TOKYO--(BUSINESS WIRE)--Data from the AZTOUND trial evaluating oral azacitidine and cedazuridine in patients with MDS or CMML will be shared at the 68th ASH Annual Meeting.

CONCORD, Mass.--(BUSINESS WIRE)--A Tier 1 academic medical center moved roughly 250 TB of legacy pathology slide data onto Corista’s DP3 image management platform.

UPPER NYACK, N.Y.--(BUSINESS WIRE)--Six Global Healthy Living Foundation Abstracts Accepted for national arthritis medical conference.

PHOENIX--(BUSINESS WIRE)-- #EmeraNova--EmeraNova™, a Phoenix-based medical technology company specializing in advanced tissue restoration technologies, is amplifying its mission to seek out new innovations and bring them to market through the launch of Catalyst. Catalyst, an EmeraNova™ Accelerator, is a four-month accelerator designed for startups at the frontier of tissue restoration and advanced wound care, which will include validation, mentorship, and investment opportunities. Applications are open now.C

MENLO PARK, Calif.--(BUSINESS WIRE)--Orca Bio to present new data at the annual American Society of Hematology Annual Meeting (ASH).

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Rx announced today that it has been selected by Bristol Myers Squibb to dispense ZENBEXUS™ (iberdomide), the first cereblon E3 ligase modulator (CELMoD) therapy approved by the U.S. Food and Drug Administration (FDA). ZENBEXUS is approved, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodul

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition (December 12–15, 2026). These latest clinical milestones demonstrate transformative progress across Gilead and Kite’s pipeline and portfolio, from new data for the investigational anitocabtagene autoleucel (anito-cel) in relapsed or

PHILADELPHIA--(BUSINESS WIRE)--The Penn-BioNTech Innovative Therapeutics Seed Fund (PxB Fund) today announced its investment in Emvena Therapeutics, a biotechnology company developing mRNA medicines designed to deliver treatments directly to the placenta to address serious maternal and fetal conditions. Emvena is the first company launched and financed by the PxB Fund, which supports the translation of promising University of Pennsylvania research for the advancement of human health. Emvena’s l

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeOne--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review to the supplemental New Drug Application (sNDA) for BRUKINSA® (zanubrutinib) in combination with rituximab for the treatment of adult patients with previously untreated mantle cell lymphoma (MCL). The application is supported by data from the pivotal Phase 3 MANGROVE

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the successful completion of its previously announced acquisition of Proscia®, a leading provider of digital-pathology software for clinical and life-sciences customers. Under the terms of the transaction, Agilent acquired Proscia for $240 million in cash at closing, with up to an additional $30 million payable based on the achievement of future performance milestones. Following the closing of the transact

BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class cancer therapies, today announced the presentation of initial first-in-human clinical data from the ongoing Phase 1 study of IM-1021, an investigational ROR1-targeted antibody-drug conjugate (ADC) for the treatment of advanced B-cell lymphomas, at the 68th American Society of Hematology (ASH) Annual Meeting. The poster will include i

PEACHTREE CORNERS, Ga.--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced that its landmark cervical cancer screening study, conducted with Türkiye’s Ministry of Health (TMOH), has enrolled over 250 of the expected 800 women needed to complete the study. The study, funded by TMOH, is intended to support Türkiye’s plan to use LuViva to screen up to 20 million Türkish women annually. Said Mark Faupel, GTHP’s CEO, “While we are stil

CHENGDU, China--(BUSINESS WIRE)--Chengdu Zenitar Biomedical Technology Co., Ltd. (Zenitar) is developing flonoltinib maleate (FM), a first-in-class oral JAK2/FLT3/CDK6 inhibitor for myeloproliferative neoplasms (MPNs), including myelofibrosis (MF) and polycythemia vera (PV). Zenitar launched randomized Phase 2 FM-MF-02 (NCT07750574) in the US, Canada and Brazil to select Phase 3 dose for JAKi-naïve and refractory MF. Randomized FMF-02 (NCT06457425) met its week-24 endpoints: superior SVR35 and

LONDON--(BUSINESS WIRE)---- $SLN #SenseofSilence--Silence Therapeutics plc (Nasdaq: SLN), a global clinical-stage biotechnology company developing novel siRNA (short interfering RNA) therapies, today announced that data from its SANRECO Phase 2 study of divesiran, a first-in-class siRNA silencing TMPRSS6, in polycythemia vera (PV) was accepted for oral presentation at the 68th American Society of Hematology (ASH) Annual Meeting being held December 12-15, 2026 in New Orleans, LA. Presentation Details: Presenting Author:

MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sumitomo Pharma America, Inc. (SMPA) today announced two oral presentations and two poster presentations at the 68th American Society of Hematology (ASH) Annual Meeting & Exposition, taking place December 12-15, 2026, in New Orleans, Louisiana. The presentations will feature new clinical data on enzomenib, an investigational oral small molecule menin inhibitor being studied in genetic subtypes of relapsed or refractory (R/R) acute leukemia (AL), and nuvi

MILPITAS, Calif.--(BUSINESS WIRE)--BlueFlag Security, the Developer Risk and Governance Platform, today announced expanded AI Agent Governance that fully maps the access, behavior and oversight of both approved and shadow AI agents, including options for automated risk remediation. Activated within BlueFlag’s pioneering platform, customers can now govern all aspects of AI agents and their relationships with human/machine identities, tools, pipelines and production applications across the softwa

CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Host Investor Event at ObesityWeek® 2026 Featuring Leading PBH Experts

COPENHAGEN, Denmark--(BUSINESS WIRE)--Genmab A/S (Nasdaq: GMAB) announced today that 22 abstracts evaluating epcoritamab, a subcutaneous T-cell engaging bispecific antibody, will be presented or published at the 68th Annual Meeting and Exposition of the American Society of Hematology (ASH), taking place December 12-15, 2026, in New Orleans, Louisiana, and virtually. The breadth of data to be shared at ASH reflects continued progress across the comprehensive epcoritamab development program, incl

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- #biotech--Immuto Scientific to Present Structural Surfaceomics Data on Novel Drug Targets for CRC and AML at ENA 2026 and ASH 2026

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY #ASH26--Incyte to Present New Data Highlighting Progress Across its Hematology Portfolio at ASH 2026

DALLAS & OSS, Netherlands--(BUSINESS WIRE)--Trained Therapeutix Discovery ("TTxD"), a pioneering immunotherapy company founded by the Jean Boulle Group and the Heritage Group, which is developing nanomedicines to regulate innate immunity, announces the appointment of Andrew Glass as Chief Executive Officer with immediate effect. Mr. Glass has more than 20 years of leadership experience in the life sciences industry as Chief Executive Officer of Vivasure Medical and previously from over 15 years

DENVER--(BUSINESS WIRE)--HepQuant to present five abstracts at AASLD The Liver Meeting® 2026 on HepQuant DuO® and its Disease Severity Index for liver disease assessment.

CORALVILLE, Iowa & FARGO, N.D.--(BUSINESS WIRE)-- #Aldevron--New Integrated DNA Technologies and Aldevron mRNA solutions help researchers simplify and optimize base and prime editing workflows.

AUSTIN, Texas--(BUSINESS WIRE)---- $HYFT #ai--MindWalk Holdings Corp. (“MindWalk”) (NASDAQ: HYFT), a Bio-Native AI company, today announced a multi-year agreement with Teva Pharmaceuticals Australia Pty Ltd (“Teva Australia”) to deploy ReefIQ™, MindWalk’s HYFT®-powered biological context layer with specified LensAI™ analytical capabilities, in support of a defined scope of antibody-discovery work. Teva Australia will use the AI capabilities to support discovery decisions based on generated predictions and ac

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing novel neuroplastogenic small-molecule therapeutics to address psychiatric and neurological disorders, today announced results from a quantitative electroencephalography (qEEG) study of its lead candidate, EB-003, in mice. The study demonstrated modulation of brain activity in prefrontal and parietal regions of the cortex, providing functional evidence of central

SAN JOSE, Calif.--(BUSINESS WIRE)--Evident Vascular, Inc., today announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Evident Vascular® Guidance System and Evident® peripheral imaging catheters. The Evident Vascular Guidance System is intended for ultrasound examination of intravascular pathology during peripheral vascular interventions. The Evident platform is designed to transform the IVUS imaging experience by bringing together high-fidelity imaging, purpose-built AI, an

PHILADELPHIA--(BUSINESS WIRE)--FORE Biotherapeutics, a registration stage biotherapeutics company dedicated to developing targeted therapies to treat patients with cancer, today announced two abstracts that have been selected for presentation at two prestigious oncology medical meetings. The first is an oral presentation highlighting long-term efficacy and safety data from a Phase 1/2a study evaluating plixorafenib in patients with BRAF V600 primary CNS tumors and will be presented at the upcom

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Jefferies Global Healthcare Conference on Wednesday, November 18, 2026, at 10:00 a.m. GMT (5:00 a.m. ET) in London. A live audio webcast of the presentation will be available in the Investors section of the Company’s website at www.alnylam.com/events. A replay will be posted on the website within 48 hours a

CULVER CITY, Calif. & DUBLIN--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX), a commercial-stage immunotherapy company, today announced that the first patients in Europe received treatment with ANKTIVA® (nogapendekin alfa inbakicept) in combination with Bacillus Calmette-Guérin (BCG) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with carcinoma in situ (CIS) with or without papillary tumors. The treatments were administered in Germany and Austria, marking an important step i

BOSTON & BRISBANE, Australia--(BUSINESS WIRE)-- #alphatherapies--AdvanCell Strengthens Leadership with Appointment of Andy Porter as Chief People Officer and Martin Huber, M.D., to its Board of Directors

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Circle Pharma, Inc., a clinical-stage biopharmaceutical company pioneering next-generation targeted macrocycle therapeutics for cancer, today announced management will participate in two upcoming investor conferences in November:Stifel 2026 Healthcare ConferencePresentation: Thursday, November 12, 2026, 1:30 p.m. ETParticipants: David J. Earp, J.D., Ph.D., president and chief executive officer; Rob Lauzen, chief financial officerLocation: New York, N

PITTSTOWN, N.J.--(BUSINESS WIRE)-- #TeamBAYER--In 2026, Bayer and America’s Grow-a-Row continued their longstanding partnership to combat food insecurity and expand access to fresh, nutritious produce for communities across the United States. Key Facts More than 200 Bayer employees volunteered with America’s Grow-a-Row on August 27 and October 1. Volunteers harvested 165,500 pounds of produce, equivalent to approximately 662,000 servings. Since 2020, Bayer Fund has provided more than $500,000 in grants to A

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte (Nasdaq:INCY) announced today that it will present at the following investor conferences during the month of November: Wolfe Research Healthcare Conference on Tuesday, November 10, 2026 at 10:00 am (EST) Jefferies Global Healthcare Conference on Tuesday, November 17, 2026 at 9:00 am (GMT) UBS Global Biopharma Conference on Tuesday, November 17, 2026 at 1:20 pm (GMT) The presentations will be webcast live and can be accessed at Investor.Incyte.com and wi

BERKELEY, Calif.--(BUSINESS WIRE)--Kimia Therapeutics Advances Oncology Asset to Clinical Stage in Collaboration with CStone Pharmaceuticals

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has completed a refinancing with funds managed by Sixth Street that lowers its borrowing costs, improves near-term liquidity, extends its debt maturity, and increases financial and operational flexibility. The transaction retires Arrowhead’s existing $400 million Sixth Street facility at a $68 million discount to the contractual minimum repayment amount and establishes a new $400 million Si

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today reported financial results and recent business updates for the third quarter ended September 30, 2026. "We are highly encouraged by the strength of Lumvoa's early launch in TED, which has exceeded expectations," said Steve Mahoney, President and Chief Executive Offi

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended September 30, 2026. Third Quarter Financial Highlights: Revenue of $842.0 million, up 19.2%, or 19.6% in constant currency, slightly above the high end of the Company’s guidance range of 17.5% - 19.5% at constant currency rates Total Omnipod revenue o

AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced three peer-reviewed publications in npj Precision Oncology, JAMA Otolaryngology, and Advances in Radiation Oncology, highlighting the performance of its Signatera test in head and neck squamous cell carcinoma (HNSCC).HNSCC carries recurrence rates of up to 60% depending on stage, and traditional surveillance modalities (e.g., imaging) are limited by high rates of

BROOMFIELD, Colo.--(BUSINESS WIRE)--Swisslog Healthcare, a global industry leader of pharmacy and transport automation solutions, introduced new pharmacy automation innovations to the Brazilian market at the VIII Simpósio Internacional Einstein de Farmácia Hospitalar, Clínica, Radiofarmácia, Pesquisa Clínica, Automação e Oncologia, held Oct. 29 and 30, 2026, at the Centro de Ensino e Pesquisa Einstein in São Paulo, Brazil. The debut reflects a 12-year partnership with Hospital Israelita Albert E

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories Announces Third-Quarter 2026 Results

BOSTON & NEW YORK--(BUSINESS WIRE)--Sapphiros, a diagnostics platform backed by investment funds managed by KKR, and binx health, a point-of-care diagnostics company backed by Hildred, a health care-focused private equity firm, today announced that they have combined to form Onvaro, a next-generation diagnostics company built to bring fast, accurate, and affordable testing to the point of need across health care and consumer settings. As part of this combination, investment funds managed by KKR

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (NASDAQ: ANTX), a clinical-stage biopharmaceutical company discovering and developing novel small molecule therapeutics derived from its boron chemistry platform, today announced the advancement of AN2-504661, a novel boron-based ENPP1 inhibitor, as a development candidate for the treatment of HPP. AN2-504661 was selected following extensive lead optimization and preclinical evaluation demonstrating the potential for a differentiated p

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced financial results for the three and nine months ended September 30, 2026. Frank H. Laukien, Bruker’s President and CEO, commented: “Bruker drives significant advances in post-genomic drug discovery and disease biology research, from proteoforms to glycobiology, and from functional protein interactions to spatial biology. These deeper insights into molecular, cell and tissue biology are foundational for successf

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced that it has entered into an amendment with Arena Pharmaceuticals, Inc. (Arena), a subsidiary of Pfizer Inc., which eliminates all royalty obligations under its exclusive license agreement related to ralinepag in exchange for an up-front payment of $525 million. “This transaction demonstrates our confidence in the revenue opportunity for

BOSTON & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Frontier Medicines Corporation (Frontier), a clinical-stage, AI-powered precision medicines company that discovers and develops covalent medicines for previously undruggable and hard-to-drug disease-causing targets, starting with cancer, today announced that it will present preclinical data from its FMC-242 program at the 38th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics, taking place in Barcelona, Spain, from Novem

WATERTOWN, Mass.--(BUSINESS WIRE)--Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, today announced that members of management will participate in the following investor conferences. 2026 Jefferies Global Healthcare Conference in London: Fireside Chat on Wednesday, November 18, 2026, at 2:30 p.m. GMT / 9:30 a.m. EST 9th Annual Evercore Healthcare Conference: Fires

NEW YORK--(BUSINESS WIRE)-- #ClinicalTrials--Definium Therapeutics, Inc. (Nasdaq: DFTX) (“Definium” or the “Company”), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced four poster presentations at the 2026 NEI Fall Congress taking place November 5 through 8 in Colorado Springs, CO. Positive topline results from Panorama, the Company’s second Phase 3 study of DT120 (lysergide

MOUNTAIN VIEW, Calif.--(BUSINESS WIRE)---- $anro #cns--Alto Neuroscience, Inc. (“Alto”) (NYSE: ANRO), a clinical-stage biopharmaceutical company focused on the development of novel precision medicines for neuropsychiatric disorders, today announced that on November 3, 2026, the Compensation and Management Development Committee of Alto’s Board of Directors granted a new employee an option to purchase 50,000 shares of Alto’s common stock. The stock option was granted under Alto’s 2025 Inducement Plan as a mater

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today reported that in its fiscal year 2026 fourth quarter ended September 30, 2026, revenue increased 5.5 percent to $88.4 billion. Revenue increased 5.0 percent to $337.4 billion for fiscal year 2026. On the basis of U.S. generally accepted accounting principles (GAAP), diluted earnings per share (EPS) was $2.71 for the fourth quarter of fiscal 2026, compared to $(1.75) in the prior year quarter. Adjusted diluted EPS, which is a no

CONSHOHOCKEN, Pa.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced that it is realigning its corporate and reporting structure to strengthen execution and visibility. “Over the last two years, Cencora has taken significant steps to advance our strategy through investments to further our leadership in specialty and enhance our service to our customers and partners. Our realigned organizational structure reflects our focus on ensuring Cencora is uniquely positioned as a leader in suppo

SILVER SPRING, Md. & RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended September 30, 2026. Total revenues in the third quarter of 2026 increased by four percent year-over-year to $832.5 million, compared to $799.5 million in the third quarter of 2025. “United Therapeutics is entering a period of extraordinary growth. We are advancing a portfolio of new therapies

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Stifel 2026 Healthcare Conference on November 11, 2026 and will participate in a fireside chat at 8:40am ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/4aFtJriVa3BvDmNqmfSxma/k5kw3HNd3Rg

NORTH BETHESDA, Md.--(BUSINESS WIRE)---- $ESAB #ESAB--ESAB Corporation Announces Third Quarter 2026 Results

GLOUCESTER, England--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today reported results for the third quarter ended September 30, 2026 and raised full-year 2026 guidance. Financial Summary and Highlights(1) Third-quarter revenue of $393.1 million increased 9.9% on a reported basis and 10.0% on a constant-currency basis as compared to the prior-year period Third-quarter U.S. GAAP diluted earnings per share of $0.11 and adjusted diluted earnings per

KOFU, Japan--(BUSINESS WIRE)-- #celltherapy--The XXI edition of Fujio Cup Quiz (FCQ) in NCRM NICHE 2026, hosted by GN Corporation, Japan and Nichi-In centre for Regenerative Medicine (NCRM), was won by Sameer Kumar Reddy and Chava Aravind Kumar from Kamineni Academy of Medical Sciences and Research Centre, Hyderabad, India. Ganga Anand Desai and Amith Mathew from Sri Ramachandra Institute of Higher Education and Research, Chennai, India, came runners. International regenerative medicine event, NCRM NICHE, hos

OAKLAND, Calif.--(BUSINESS WIRE)-- #CWCI--Average meloxicam payments in California workers' comp are up sharply and the drug consumed more than 30% of the anti-inflammatory drug spend in 2025.

NEWBURYPORT, Mass.--(BUSINESS WIRE)--UFP Technologies, Inc. (Nasdaq: UFPT), a trusted contract development and manufacturing organization specializing in comprehensive solutions for medical devices, sterile packaging and other highly engineered custom products, today reported net income of $20.6 million for its third quarter ended September 30, 2026, 25.8% higher than net income of $16.4 million for the third quarter of 2025. Net sales for the quarter ended September 30, 2026 were $172.4 millio

SAN DIEGO--(BUSINESS WIRE)--Avenzo Therapeutics to Participate at Upcoming Investor Conferences

PALO ALTO, Calif.--(BUSINESS WIRE)--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced the appointment of Kevin Sayer to its board of directors. Mr. Sayer is former CEO of Dexcom, Inc. and current Executive Chairman of the Dexcom board, with decades of strategic leadership experience in digital health technology. “We are excited to welcome Kevin Sayer to Guardant’s board,” said Helmy Eltoukhy, chairman and co-CEO of Guardant Health. “Kevin has played a piv

SAN DIEGO--(BUSINESS WIRE)---- $TVTX--Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that company management will participate in the following upcoming investor conferences:Guggenheim Global Healthcare ConferencePresenting on Tuesday, November 10, 2026, at 8:00 a.m. ETStifel 2026 Healthcare ConferencePresenting on Wednesday, November 11, 2026, at 3:20 p.m. ETUBS Global Biopharma ConferencePresenting on Monday, November 16, 2026, at 11:20 a.m. GMTJefferies London Healthcare ConferencePresenting

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, announced the global launch of Simon™, a cloud-native, vendor-agnostic command center for linear accelerator (linac) health in radiation oncology. Working alongside SunCHECK® software or independently, Simon brings quality assurance (QA) data from across devices, vendors and sites into one comparable record, giving medical physicists a single view of machine health, from individual linacs to an entire network. By applying s

TEANECK, N.J.--(BUSINESS WIRE)--The Board of Directors of Phibro Animal Health Corporation (Nasdaq: PAHC) today declared a quarterly cash dividend of $0.12 per share on its Class A common stock and Class B common stock, payable on December 16, 2026, to stockholders of record at the close of business on November 25, 2026. About Phibro Animal Health Corporation Phibro Animal Health Corporation is a leading global diversified animal health and nutrition company. We strive to be a trusted partner w

SAN DIEGO--(BUSINESS WIRE)--Contineum Therapeutics, Inc. (NASDAQ: CTNM) (Contineum or the Company), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today reported its third-quarter 2026 financial results. “Lysophosphatidic acid 1 receptor (LPAR1) antagonism as a treatment approach for pulmonary fibrosis has exceptionally strong clinical validation with multiple trials successfully c

REDWOOD CITY, Calif.--(BUSINESS WIRE)--Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today reported its results for the third quarter. Financial Results “Awareness of the importance of diagnosing and treating patients with Cushing’s syndrome is steadily increasing and is driving the

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced that company management will participate in fireside chats at the following investor conferences in November:Guggenheim 3rd Annual Healthcare Innovation Conference: Exelixis is scheduled to present at 9:30 a.m. ET / 6:30 a.m. PT on Tuesday, November 10 in Boston.Stifel 2026 Healthcare Conference: Exelixis is scheduled to present at 1:20 p.m. ET / 10:20 a.m. PT on Wednesday, November 11 in New York City.UBS Global Bio

GUILFORD, Conn.--(BUSINESS WIRE)--Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced that management will host investor meetings at two healthcare conferences in November. UPCOMING CONFERENCES 2026 Jefferies Global Healthcare Conference in London - Wednesday, November 18 and Thursday, November 19, 2026. Management will be hosting in

BURLINGTON, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) ("Myomo" or the "Company"), a wearable medical robotics company that offers increased functionality for those suffering from neurological disorders and upper-limb paralysis, today announced its participation at the 17th Annual Craig Hallum Alpha Select Conference being held Tuesday, November 17, 2026, at the Sheraton New York Times Square Hotel. Myomo’s President and Chief Executive Officer Paul Gudonis, Chief Financial Office

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST): UNITED STATES DISTRICT COURT DISTRICT OF DELAWARE IN RE TWIST BIOSCIENCE CORPORATION DERIVATIVE LITIGATION Lead Case No. 1:23-cv-01048-MN SUMMARY NOTICE OF PROPOSED SETTLEMENT OF DERIVATIVE ACTION TO: ALL CURRENT RECORD HOLDERS AND BENEFICIAL OWNERS OF TWIST BIOSCIENCE CORPORATION (“TWIST” OR THE “COMPANY”) COMMON STOCK AS OF OCTOBER 15, 2026 (THE “RECORD DATE”). IF YOU WERE A RECORD OR BENEFICIAL OWNER O

ROCHESTER, N.Y.--(BUSINESS WIRE)--Transcat Reports Strong Fiscal Second Quarter 2027 Financial Results with Double-Digit Service Organic Revenue Growth, Service Gross Margin Expansion

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update

MASON, Ohio--(BUSINESS WIRE)--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management and post-operative pain management, today announced third quarter 2026 financial results. “Our third quarter results demonstrate the strength of our broad portfolio and our team’s disciplined execution,” said Michael Carrel, President and Chief Executive Officer. “Adoption of our innovative technologies is dr

PASADENA, Calif.--(BUSINESS WIRE)--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on November 12, 2026, at 4:30 p.m. ET to discuss its financial results for the 2026 fiscal year ended September 30, 2026.Webcast and Conference Call DetailsInvestors may access a live audio webcast on the Events and Presentations page under the Investors section of the Arrowhead website. A replay of the webcast will be available approximately two hours

DUBLIN--(BUSINESS WIRE)--Alkermes plc (Nasdaq: ALKS) announced today that management will participate in two upcoming investor conferences. Stifel 2026 Healthcare Conference Date/Time: Fireside chat on Tuesday, Nov. 10, 2026 at 10:40 a.m. ET (3:40 p.m. GMT) Jefferies Global Healthcare Conference in London Date/Time: Fireside chat on Wednesday, Nov. 18, 2026 at 11:30 a.m. ET (4:30 p.m. GMT) The live webcasts may be accessed under the Investors tab on www.alkermes.com and will be archived for 14

WASHINGTON--(BUSINESS WIRE)--Kristie Mark, Chief Operating Officer of The ESOP Association, named Executive Director of the Employee Ownership Foundation.

CAMPBELL, Calif.--(BUSINESS WIRE)--Imperative Care’s first-in-field analysis provides encouraging safety findings for women with pulmonary embolism.

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Rx announced today that it has been selected by Bristol Myers Squibb to dispense ZENBEXUS™ (iberdomide), the first cereblon E3 ligase modulator (CELMoD) therapy approved by the U.S. Food and Drug Administration (FDA). ZENBEXUS is approved, in combination with daratumumab and hyaluronidase-fihj and dexamethasone, for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodul

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, announced the global launch of Simon™, a cloud-native, vendor-agnostic command center for linear accelerator (linac) health in radiation oncology. Working alongside SunCHECK® software or independently, Simon brings quality assurance (QA) data from across devices, vendors and sites into one comparable record, giving medical physicists a single view of machine health, from individual linacs to an entire network. By applying s

ALACHUA, Fla.--(BUSINESS WIRE)--Neurotronics, a Nihon Kohden company, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for its Sleep Analysis Module (SAM).SAM is a software-only medical device that includes a total sleep time (TST) algorithm. The algorithm analyzes a photoplethysmography (PPG) signal to estimate TST and aid health care professionals in the evaluation of sleep disorders.SAM represents the first FDA-cleared AI/ML-based sleep analysis al

NEW YORK--(BUSINESS WIRE)--Definium Therapeutics, Inc. (Nasdaq: DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company’s management team will participate in the following investor conferences: Stifel 2026 Healthcare Conference Fireside Chat Date and Time: Tuesday, November 10, 2026 at 9:20 AM ET Loc

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences:Stifel Healthcare Conference on Tuesday, November 10, 2026, at 8:40 a.m. ET in New York City, NYJefferies Global Healthcare Conference on Wednesday, November

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Jefferies Global Healthcare Conference, which is being held November 16-19, 2026 at the Waldorf Hilton and ME Hotel in London, UK. Management will participate in a fireside chat on Monday, November 16th at 11:30 a.m. Greenwich Mean Time (6:30 a.m. Eastern Time). A live audio webcast of the fireside chat will be accessible under the “Events” section of the company’s investor relations website:

POOLER, Ga.--(BUSINESS WIRE)--Porter Logistics, a Georgia third-party logistics (3PL) company with warehouses in Atlanta and Savannah, operates the new Teckrez Distribution Center, which held its grand opening and ribbon cutting on Wednesday, Oct. 28, at Porter's Savannah 3PL warehouse at 195 Nordic Way in Pooler. Teckrez, a Jacksonville-based supplier of hydrocarbon resins and monomers, selected Porter to run the center, which opened in February. The center receives Teckrez's import containers

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, has appointed Wetteny Joseph as Group President, Pharma and Consumer Health (PCH), effective today. Joseph will lead Catalent’s PCH segment focusing on oral delivery technologies and manufacturing for small and macro molecules, and advanced delivery of self-care solutions, joining Catalent’s Group Executive Commi

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, an agentic AI and real-world data (RWD) company advancing oncology drug development, commercialization, and access to precision medicine, today announced a partnership with Global Leadership in Oncology & Wellness (GLOW), a 501(c)(3) non-profit dedicated to bridging the gap between patients, caregivers, and the scientific community. Through the partnership, the organizations will work together to connect patients and caregivers in GLOW’s commu

BURLINGTON, Mass.--(BUSINESS WIRE)--PharmaEssentia USA Corporation, a subsidiary of PharmaEssentia Corporation (TWSE: 6446), a global biopharmaceutical innovator based in Taiwan leveraging deep expertise and proven scientific principles to deliver new biologics in hematology and oncology, today announced that members of its management team will participate in the following investor conferences: Jefferies London Healthcare Conference Date: November 16-19, 2026 Location: London, United Kingdom Ci

ATLANTIC BEACH, Fla.--(BUSINESS WIRE)-- #AI--nPhase, Inc., today announced the closing of a $30 million Series D funding round led by Viking Global Investors to accelerate the company’s AI-native clinical data platform for pharmaceutical sponsors seeking to unlock the full potential of their data and power AI at scale. Viking Global Investors is an investment firm managing more than $54 billion in capital across public and private investments. The financing represents nPhase’s first equity capital ra

HANGZHOU, China & NEWARK, Calif.--(BUSINESS WIRE)--Phase 2b/3 trial results show lingdolinurad significantly outperformed febuxostat in treating chronic gout and hyperuricemia

BEIJING & CLEARWATER, Fla.--(BUSINESS WIRE)--Darwin Biotech (“Darwin”), a clinical-stage company developing treatments for neurological diseases, today announced that data from its randomized, double-blind, placebo-controlled Phase 1 study of ALT001 in amyotrophic lateral sclerosis (ALS), including 12-week results from an ongoing open-label extension (OLE), were presented in a poster at the 2026 Network of Excellence for ALS (NEALS) Annual Meeting, taking place October 27-30 in Clearwater, Flor

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced the company will report financial results for the third quarter of 2026 on Thursday, November 12, 2026. Management will hold a conference call beginning at 4:30 pm Eastern time to review the results, provide a business update and answer questions.Participants are en

MIAMI & NEW YORK--(BUSINESS WIRE)-- #ClinicalAI--NYU Langone Health, one of the nation’s premier academic health systems and ranked No.1 in the nation for quality by Vizient, Inc., and OpenEvidence, the most popular AI for doctors in the United States, today announced a collaboration to bring OpenEvidence directly into NYU Langone’s Epic electronic health record (EHR), with Patient Aware Clinical Intelligence. Clinicians across NYU Langone will now be able to ask complex clinical questions in natural languag

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)-- #futuredoctors--Kaplan launches innovative USMLE prep platform featuring personalized learning, adaptive study plans, and tools to help future physicians succeed.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced its third-quarter results for the period ended September 30, 2026.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today reported financial results for the third quarter ended September 30, 2026 and updated its financial guidance for the full year ending 2026. Third Quarter 2026 Highlights(1) Sales of $335.6 million decreased 0.7% year-over-year as reported and decreased 0.8% on a constant currency(2) basis. Excluding the impact of the Company’s previously announced strategic exits of GI product offerings, net sales increased 6.7% on an organic c

MIAMI & ROCKVILLE, Md.--(BUSINESS WIRE)-- #ClinicalAI--The American Society of Addiction Medicine (ASAM) and OpenEvidence, the most popular AI for doctors in the United States, today announced a collaboration to make ASAM’s clinical guidelines, guidance, and implementation resources accessible through OpenEvidence. This integration enables OpenEvidence’s clinician users to readily access ASAM’s evidence-based guidance for the care of patients with substance use disorders (SUD) and addiction. ASAM’s guidance

NAARDEN, Netherlands & WALTHAM, Mass. & BARCELONA, Spain--(BUSINESS WIRE)-- #ALS--Prilenia Therapeutics B.V. and Ferrerii today announced the presentation of new data and PREVAiLS study updates at the upcoming Northeast Amyotrophic Lateral Sclerosis (NEALS) Consortium 2026 annual meeting in Florida. In a new post hoc analysis of a sub-group of 36 participants with definite or probable ALS (El Escorial Criteria) who are within 18 months from first onset of disease symptoms from the Phase 2 HEALEY Platf

HOUSTON--(BUSINESS WIRE)--Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance Treg function, announces a poster presentation at the 2026 Annual NEALS Meeting on October 28th in Clearwater, Florida. NEALS (Network of Excellence for ALS) is the world’s largest ALS research consortium, dedicated to accelerating the development of new treatments for ALS and Motor Neuron Disease (MND). Coya is currently con

SARASOTA, Fla. & AUSTIN, Texas--(BUSINESS WIRE)--Deep Reasoning AI Inc., a company founded by Cornell University artificial intelligence professors, today announced that the U.S. Food and Drug Administration has granted 510(k) clearance (K262134) for NeuroDR, its AI-enabled software for visualizing the arteries of the head and neck from CT angiography (CTA) scans. NeuroDR was developed in collaboration with 3DR Labs, the largest provider of 3D medical image post-processing in the United States,

HOUSTON--(BUSINESS WIRE)--The Walmart Healthcare Research Institute (WHRI) and Care Access, a health and research company, today announced plans to open three additional Clinical Trial Centers in Livonia, Michigan; Las Vegas, Nevada; and San Antonio, Texas in the first half of 2027. The expansion builds on the recent opening of the partnership’s first four centers in Houston and Tyler, Texas; Dalton, Georgia; and Brandon, Florida bringing health screenings and clinical research opportunities int

QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced that management will be attending the following investor conferences: UBS Global Healthcare Conference on Tuesday, November 10, 2026 in Palm Beach Gardens, FL Canaccord Genuity's MedTech, Diagnostics and Digital Health & Services Forum on Wednesday, November 11, 2026 in New York, NY Craig-Hallum A

NEW YORK & BURLINGTON, Mass.--(BUSINESS WIRE)---- $BFLY #POCUS--Butterfly Network, Inc. (NYSE: BFLY) (“Butterfly”), a pioneer and leader in semiconductor-based ultrasound devices, cloud software and AI, today announced that it will attend the UBS Global Healthcare Conference in Palm Beach Garden, FL on November 10, 2026. Joseph DeVivo, President, Chief Executive Officer & Chairman and John Doherty, EVP, Chief Financial Officer, will present and host one-on-one investor meetings. The company presentation wil

MĀHIA, New Zealand--(BUSINESS WIRE)--(MĀHIA SPACEPORT) – SFL Missions Inc. today confirmed the successful deployment of six radio frequency (RF) detection and geolocation satellites for HawkEye 360 of Herndon, Va. SFL Missions delivered the HawkEye 360 Cluster 15 and 16 spacecraft bus units and subsystems with advanced capabilities to HawkEye 360’s facility in Virginia for assembly, integration, and testing under the SFL Flex Production Program. A total of 48 operational HawkEye 360 RF geolocat

HOUSTON--(BUSINESS WIRE)--Voyager Technologies (NYSE: VOYG) executed a mission management contract with Interstellar Lab to host BioPod EDEN, the company’s autonomous plant growth payload, aboard the International Space Station (ISS). “Commercial companies are now delivering research capabilities that governments, space agencies and researchers around the world can put to work on the International Space Station,” said Mattia Pianorsi, managing director, Voyager Technologies Europe. “Our role is

FLORHAM PARK, N.J.--(BUSINESS WIRE)--Shionogi Inc., a New Jersey-based subsidiary of Shionogi & Co., Ltd., (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D.), will present three posters at the 2026 Annual Network of Excellence for Amyotrophic Lateral Sclerosis (NEALS) Meeting, taking place October 27-30 in Clearwater, Florida. Shionogi remains committed to advancing ALS research and expanding the understanding of RADICAVA ORS® (edaravone), including through real-wor

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Acelot, a biotechnology company developing small molecule therapies for challenging targets in diseases with high unmet need, today announced that Acelot CMO & CDO Mark Forman, MD, PhD, will present preclinical data from the company’s TDP-43 program at the upcoming 2026 Annual Network of Excellence for ALS (NEALS) meeting, taking place October 27-30 in Clearwater, FL and virtually. Additionally, Acelot CEO Katie Planey, PhD, MBA, will participat

ORLANDO, Fla. & LITTLETON, Mass.--(BUSINESS WIRE)-- #MevionFIT--Adults and children facing cancer will have access to more advanced treatment options close to home as the AdventHealth Cancer Institute introduces proton therapy. The MEVION S250-FIT™ Proton Therapy System will expand the care available to Central Floridians. AdventHealth Cancer Institute brings together cancer specialists, advanced treatments, clinical research and services that support patients’ physical, emotional and spiritual needs. Its n

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that its partner Akeso Inc. announced positive results from the Phase III HARMONi-GI1 study evaluating the novel, potential first-in-class investigational bispecific antibody ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). These data are featured in today’s Presidential Symposium II at the European Society for Medic

MIAMI & SEOUL, South Korea--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) and Lunit Inc. (KRX: 328130) today announced a research agreement to evaluate the use of Lunit SCOPE IO, Lunit’s AI-powered pathology platform, for tumor microenvironment analysis in support of Summit’s immuno-oncology development programs with ivonescimab. The effort will focus on applying Lunit SCOPE IO to hematoxylin and eosin-stained (H&E) whole-slide images to characterize tumor microenvironment featur

WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Medical Manufacturing Technologies (MMT), a leading provider of medical device and industrial manufacturing equipment, automation, and process expertise, today announced the launch of its redesigned website. As the first of its kind in the manufacturing solutions industry, this intuitive digital experience redefines how manufacturers access specialized technical expertise and identify tailored solutions to improve production performance. Reflecting MMT’s

PHILADELPHIA--(BUSINESS WIRE)--Datavault AI Inc. (“Datavault AI” or the “Company”) (Nasdaq: DVLT), an Artificial Intelligence Platform (“AIP”) company providing data monetization, credentialing, and real-world asset (“RWA”) tokenization, today announced that it has entered into a non-binding letter of intent (“LOI”) to acquire a 19.9% equity interest in DataMEDS AI, Inc. (NASDAQ: MEDS) (“DataMEDS”) in consideration of an expansion of its existing technology license with DataMEDS. The proposed t

BOCA RATON, Fla. & SOMERSET, N.J.--(BUSINESS WIRE)-- #AAPS--The acquisition is part of LGM Pharma's strategy to build a U.S.-based analytical services platform alongside its API sourcing business.

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced that ivonescimab data will be featured in numerous presentations at the European Society for Medical Oncology 2026 Congress (ESMO 2026), taking place October 23-27, 2026, in Madrid, Spain. Across 10 presentations at ESMO 2026, ivonescimab data will span a broad range of tumor types, led by positive overall survival findings from Akeso Inc.’s Phase III HARMONi-GI1 study of ivonescimab plus chemotherapy compared to du

CONSHOHOCKEN, Pa. & FORT MYERS, Fla.--(BUSINESS WIRE)--Cencora, Inc. (NYSE: COR) today announced it has signed a definitive agreement to acquire American Oncology Network, Inc. (“AON”) (OTCQX: AONC), a physician-led network of more than 350 oncology providers across 21 states. “The acquisition of AON will expand our physician-led oncology MSO and support of care in communities across the country,” said Robert P. Mauch, President and Chief Executive Officer of Cencora. “AON serves as a trusted p

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced a clinical trial collaboration with the ECOG-ACRIN Cancer Research Group (ECOG-ACRIN) to evaluate ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in a registration-enabling Phase II/III study in biliary tract cancer (BTC). The new study, EA2251 (NCT07765433), is designed to evaluate the safety and efficacy of ivonescimab with chemotherapy compared to pembrolizumab or durvalumab pl

ENGLEWOOD, N.J.--(BUSINESS WIRE)--CD206-targeted glucocorticoid 101-PGC-005 beat dexamethasone in 309-patient Phase 2/3 trial (HR 2.31); steroid-sparing data at ACR Poster 0122, Nov 8

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, a leader in remote physiologic monitoring (also known as remote patient monitoring or RPM) solutions, today announced two new offerings for qualifying healthcare providers: free patient onboarding and engagement services to improve device use and adherence through its signature SmartTouch® program, and lower monthly service fees. Together, they are designed to help practices start, scale, and sustain RPM programs at a time when administrative demands a

BOCA RATON, Fla.--(BUSINESS WIRE)--Algia Pharma, LLC (“Algia”) today announced the successful completion of its Investigational New Drug (IND)-enabling preclinical toxicology study for AlgiaPak®. AlgiaPak is a hospital-grade multimodal pain regimen designed to treat all mild-to-moderate acute pain as effectively as opioids, without exposing patients to the risk of opioid addiction. Results from the study, conducted in full compliance with Good Laboratory Practice (GLP) standards, demonstrated t

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the initiation and opening of clinical trial sites of a multiregional Phase II study of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in previously untreated advanced clear cell renal cell carcinoma (ccRCC), the most common form of kidney cancer. The study (SMT112-216 / AK112-216 / NCT07877194) is being conducted in collaboration with Summit’s partner, Akeso Inc. SMT

WALTHAM, Mass.--(BUSINESS WIRE)--Palleon Pharmaceuticals, a clinical-stage biotechnology company developing novel therapeutics for autoimmunity and cancer, will deliver an oral presentation at the 2026 American College of Rheumatology (ACR) Convergence, taking place November 6-11 in Orlando, Florida. Palleon's presentation will take place on Wednesday, November 11. Details of Palleon's Presentation: American College of Rheumatology (ACR) Convergence Title: Rapid and deep clinical responses to H

MIAMI--(BUSINESS WIRE)-- #COVID19--AIDS Healthcare Foundation (AHF) welcomes the United Nations General Assembly’s adoption of the Political Declaration on Pandemic Prevention, Preparedness, and Response, with 153 countries voting in favor and only three against. AHF urges governments to turn this strong affirmation of international cooperation into concrete commitments that protect people from future pandemics. “Effective coordination on pandemic prevention, preparedness, and response is of utmost import

NEW YORK--(BUSINESS WIRE)--Fortell today announced it is expanding access to its prescription AI hearing aids across more than 30 states through new clinics and Fortell Anywhere, its remote audiology service.Fortell’s custom AI chips use spatial cues to separate speech from competing sounds in real time, directly on the device, and without a perceptible lag. By isolating voices and reducing background noise before amplification, Fortell helps people follow conversations in restaurants, crowded r

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Reservoir today launched a personal cell preservation service that lets adults preserve their own immune cells through a standard blood draw. Reservoir is available today through partner clinics in San Francisco, Boston, Los Angeles, and New York City, with in-home appointments launching in select markets. Sign up at withreservoir.com to be matched with a nearby appointment or to receive updates when Reservoir comes to your city. To see Reservoir in action, go

LAS VEGAS & PANAMA CITY--(BUSINESS WIRE)-- #AABB--Auragens, an international regenerative medicine and research institute, today announced that its research paper, "Molecular Dynamics Simulation of SOD3 and CXCR4 Proteins in Engineered Mesenchymal Stem Cells for Radiation Countermeasure Therapeutics," has been formally accepted for presentation at the 2027 American Institute of Aeronautics and Astronautics (AIAA) SciTech Forum, taking place January 11–15, 2027, in Orlando, Florida.The paper, authored by

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics expanded its partnership with Indica Labs to scale AI-powered digital pathology and support more timely, consistent diagnostic insights.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will report its third quarter 2026 financial results after the close of the U.S. financial markets on Wednesday, October 28, 2026.

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), the company leveraging its ever evolving novel and proprietary Nanosecond Pulsed Field Ablation™ (nano-PFA or nsPFA™) technology, today announced a partnership with the Clayman Thyroid Center at the Hospital for Endocrine Surgery in Tampa, Florida. The partnership covers both the commercial use of the nPulse™ Vybrance™ Percutaneous Electrode System in the treatment of patients at the center and a clinical collaboration to

MIAMI & BALTIMORE--(BUSINESS WIRE)-- #ClinicalAI--OpenEvidence and Johns Hopkins Medicine are collaborating to design medical education and clinical care for the AI era, with patients at the center.

WALTHAM, Mass.--(BUSINESS WIRE)-- #ACR2026--Fortitude Biomedicines Announces Oral Presentation of FTB-918 for the Treatment of Axial Spondyloarthritis at ACR Convergence 2026.

NEW CASTLE, Del. & SAN ANTONIO--(BUSINESS WIRE)--IgniteData, a leader in intelligent clinical trial data automation, and RealTime eClinical Solutions, a leader in clinical research software solutions, today announced a new partnership which will provide RealTime’s network of clinical research sites with expanded access to IgniteData’s Archer platform to securely and efficiently transfer clinical data. Archer is the only platform built from the ground up solely to solve for long-standing data tr

WHITMORE LAKE, Mich. & SARASOTA, Fla.--(BUSINESS WIRE)--Trace Medical, a national leader in advanced respiratory rentals and biomedical services, announced that it has acquired a majority interest in LiViliti Health Products, Inc. The acquisition follows LiViliti receiving 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Paptizer 360 classified as a Class II Respiratory Accessory Microbial Reduction Device for CPAP equipment. The majority acquisition builds upon the exi

TAMPA, Fla. & WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, and Mantra™, a consumer health company developing single-serve, over the counter (OTC) oral gel products for everyday relief, today announced a commercial supply agreement for Mantra’s oral gel product platform. Catalent will provide formulation development, commercial manufacturing and pa

OLDSMAR, Fla.--(BUSINESS WIRE)--Cryo-Cell International, Inc. (NYSE American, Symbol: CCEL) (the “Company”, “Cryo-Cell”), the world’s first private cord blood bank to separate and store stem cells in 1992, announced results for the fiscal third quarter ended August 31, 2026. Financial Results Revenue Consolidated revenues for the third quarter of fiscal 2026 were $7.82 million compared to $7.83 million for the third quarter of fiscal 2025. Net Income The Company reported net income of $1.27 mil

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics Inc., a late-stage biopharmaceutical company developing a new class of therapeutics designed to treat eye diseases by repairing helical collagen, today announced it has submitted an investigational new drug application amendment to the U.S. Food and Drug Administration to study its lead candidate, ST-100 (vezocolmitide), in corneal wound healing. The planned proof-of-concept study would mark ST-100's first expansion beyond dry eye disease and co

BOCA RATON, Fla.--(BUSINESS WIRE)-- #LumbarDecompression--SurGenTec®, a privately held medical device company focused on advancing treatment options for orthopedic and spine surgery, today announced that it has entered into an exclusive license agreement with Allevion Medical for its patented Vantage™ spinal decompression technology. Under the terms of the agreement, SurGenTec® has secured exclusive rights to Allevion Medical's Vantage™, a fully disposable, sterile system designed to simplify and enhance minimally in

DENVER--(BUSINESS WIRE)-- #AI--Cleerly, a leader in advanced cardiovascular imaging analysis, and Clear Heart and Lung Imaging, a leader in outpatient imaging care, have taken a cardiac-capable mobile CT scanner across the southern United States to expand access to cardiovascular research and enable communities and clinics to participate in Cleerly's TRANSFORM Trial. From July through September 2026, the CT scanner traveled through Arizona, Louisiana, Georgia, and Florida, bringing cardiovascular ima

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ supersonic aircraft, today announced the completion of its first flight hardware manufactured under a production agreement with Italian engineering company Robby Moto Engineering S.R.L. ("RME"), marking an important milestone in the Company's continued development of its previously ann

LAUSANNE, Switzerland, WEST PALM BEACH, Fla.--(BUSINESS WIRE)--Timeline (Amazentis SA), the Swiss life-sciences company that pioneered the healthy aging ingredient Urolithin A and its branded form Mitopure®, together with its U.S. subsidiary Timeline Longevity, Inc., announced today that the U.S. District Court for the District of Massachusetts has granted an ex parte temporary restraining order against the operators of a network of websites that impersonate Timeline’s official site, www.timeli

LAKELAND, Fla.--(BUSINESS WIRE)--As Publix celebrates National Seafood Month, the company continues its long-standing commitment to advancing sustainable seafood by donating nearly $100,000 to Sustainable Fisheries Partnership (SFP) in 2026 alone, bringing its total contribution to the organization to more than $1.2 million.Now in its 16th year, Publix’s collaboration with the nonprofit highlights the company’s environmental stewardship and responsible sourcing efforts. SFP works with the seafoo

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #Cordis--Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the SELUTION SLR SUSTANE™ PTA Drug-Eluting Balloon (SUSTANE DEB) achieved the highest reported 12-month primary patency in the SELUTION4SFA US pivotal trial at 90.3%. The results were presented during a Late-Breaking Clinical Trial session at VIVA 2026 by Jay Mathews, MD, MS, Director, Cardiac Catheterization Laboratory, PERT & Structural Heart at

MIAMI--(BUSINESS WIRE)--DemeRx, Inc., a clinical-stage biopharmaceutical company dedicated to transforming addiction therapeutics, today announced the appointment of Juan R. Sanchez-Ramos, M.D., Ph.D., to its Scientific Advisory Board. A neurologist and clinician-scientist whose career has spanned addiction, movement disorders, and neurodegenerative diseases, Dr. Sanchez-Ramos was an early leader in the clinical investigation of ibogaine and a scientific collaborator of DemeRx founder and CEO D

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics today announced its executive leadership and board of directors succession plan.

MELBOURNE, Fla.--(BUSINESS WIRE)--Smart seating company Kalogon names former Meta, Magic Leap executive Marty Evans as its first chief technology officer.

TAMPA, Fla.--(BUSINESS WIRE)--Catalent, Inc., the leading global contract development and manufacturing organization (CDMO) dedicated to helping people live better and healthier lives, today announced the U.S. launch of an accelerated gene-to-drug substance program for complex biologics, designed to help developers move bispecifics, multispecifics and other next-generation molecules from gene sequence to drug substance in 10 months. The program builds on Catalent's Rapid Antibody offering for t

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the successful closing of AstraZeneca’s (LSE/STO/NYSE: AZN) strategic equity investment in Summit. The equity investment will support continued acceleration of the development of ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody. Pursuant to the terms of the Securities Purchase Agreement entered into by Summit and AstraZeneca, AstraZeneca purchased an aggregate of approxi

ANTALYA, Turkey & JACKSONVILLE, Fla.--(BUSINESS WIRE)---- $RDW--Redwire Corporation (NYSE: RDW), a global leader in space and defense technology solutions, today announced it has been awarded a contract by Axiom Space, a leader in next-generation space infrastructure, to develop and deliver two Roll-Out Solar Array (ROSA) wings for Axiom Station’s second space station module. As previously announced, Redwire is also building the ROSA wings for Axiom Space’s first space station module. “We are excited an

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the publication of results from its Phase 2b SUPER (Stand Up to Pertussis) clinical trial in The Lancet Infectious Diseases. This randomized, double blind, placebo- and active-comparator-controlled trial demonstrated that BPZE1, a live attenuated intranasal pertussis vaccine, induced robu

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced a clinical trial collaboration agreement with Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/NYSE: AZN) to evaluate ivonescimab, a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody, in combination with Datroway® (datopotamab deruxtecan), a TROP2-directed antibody drug conjugate (ADC), across multiple solid tumor settings, intending to include breast and lung cancer. The companies i

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced that it will report financial results for the third quarter 2026 after the market close on Wednesday, October 28, 2026. The Company’s management will host a conference call at 4:30 p.m. ET that same day to discuss the results. To participate in the conference call via live webcast, please click here. To participate via telephone, please click here to pre-register and obtain the dial-in number and passcode. This confer

ORLANDO, Fla.--(BUSINESS WIRE)-- #MedicalDevices--Xenix Medical Announces FDA Clearance of NanoACTIV™ Surface Technology for Its Riva® Posterior Fixation System.

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, Inc., an agentic AI and real-world data company advancing oncology drug development and access, today announced its inclusion in TIME’s World’s Top HealthTech Companies 2026 in the AI & Data Analytics category. Produced in collaboration with Statista, the list recognizes 500 companies worldwide based on financial performance, reputation and online engagement. The recognition comes as Massive Bio expands its role as oncology data and AI infrast

CORAL SPRINGS, Fla.--(BUSINESS WIRE)--ACIC Equipment USA will join ACIC Pharmaceuticals at CPHI Milan 2026, bringing together ACIC's pharmaceutical expertise and global network of technology partners to showcase an integrated approach to pharmaceutical development, manufacturing and commercialization. From October 6–8, 2026, visitors to Stand 7G106 can meet both teams and discover how ACIC connects pharmaceutical expertise, advanced manufacturing technologies and specialized engineering to help

BOCA RATON, Fla. & COLUMBUS, Ohio--(BUSINESS WIRE)--The TECPR2 Research Foundation, a nonprofit organization established to advance research and development of a treatment for patients with TECPR2, and Forge Biologics (“Forge”), a leading manufacturer of gene therapies and member of Ajinomoto Bio-Pharma Services, today announced a development and manufacturing partnership to advance an AAV gene therapy for patients with TECPR2, an ultra-rare neurodegenerative genetic disease. Under the partners

GAINESVILLE, Fla.--(BUSINESS WIRE)--Neuropacs™ Corp. today announced that its Co-Founder & Chief Scientific Officer, Dr. David Vaillancourt, will serve as a key scientific leader in a $22 million National Institutes of Health grant supporting the University of Florida-led Alzheimer’s Disease Research Center (1Florida ADRC). The award positions Florida among a select national network of only 37 ADRCs in the United States and the only one located in the state, expanding the region's role in a

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the lives of patients with cancer. Specifically, Summit has established agreements with AstraZeneca (LSE/STO/NYSE: AZN) for a strategic equity investment in Summit and a clinical collaboration focused on ivonescimab and sonesitatug vedotin (sone-ve). Moreover, Summit and AstraZeneca intend to evaluat

MIAMI & NUREMBERG, Germany--(BUSINESS WIRE)--DermaSensor Inc., a leader in AI-powered skin cancer risk detection technology, today announced the commercial launch of DermaSensor in Germany through a distribution agreement with ContraCare GmbH. The launch represents a significant milestone in DermaSensor’s international expansion following its recent Class IIb CE Mark under the European Union Medical Device Regulation (MDR) and collaboration with the National Health Service (NHS) in the United K

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, today announced that its AdaptCHECK™ software has been validated in collaboration with Siemens Healthineers technical experts and clinical partners for interoperability with the company's new radiotherapy system, Accela. Unveiled at the annual ASTRO conference, Accela is the first software-driven delivery system engineered for NeoArc (Dynamic Modulated Arc Therapy, DMAT), a new treatment technique that accelerates how radia

MIAMI-DADE, Fla. & BROWARD, Fla. & PALM BEACH, Fla. & DUVAL, Fla. & HILLSBOROUGH, Fla.--(BUSINESS WIRE)--Little more than half (52%) of respondents, and less than half (43%) of those aged 30-39, are very aware that breast cancer diagnoses have been rising among younger patients, according to a poll of more than 1,000 Florida-based women. Findings show 32% are somewhat aware of this increase, and 17% are either not very aware (11%) or not at all aware (6%). Conducted by the TopLine MD Alliance —

MELBOURNE, Fla.--(BUSINESS WIRE)--Sun Nuclear, a Mirion Medical company, will bring next-generation innovations for next-level confidence to the ASTRO 2026 Annual Meeting, beginning Sunday, September 27, in Boston. At Booth 915, attendees will get a first look at new solutions for radiation therapy quality assurance (QA), alongside dedicated programming on smarter QA workflows and one of oncology's fastest-growing areas: radiopharmaceutical therapy.An Exclusive Look: A New Way to See Machine Hea

EDISON, N.J.--(BUSINESS WIRE)-- #CollaborativeSurgicalIntelligence--Redefine Surgery, a medical technology company building physical AI for surgery, today announced the closing of an oversubscribed pre-seed financing round, bringing total capital raised to $10 million. Backed predominantly by surgeon investors, the financing will support continued development of the company’s surgical intelligence platform as it advances toward commercialization. The financing announcement follows Wednesday’s announcement by Catalyst OrthoScience

MIAMI & COLLEGE PARK, Md.--(BUSINESS WIRE)--IonQ (NYSE: IONQ), the world’s leading full-stack quantum platform and foundry, today announced a contract with Florida International University (FIU), Miami’s top ranked state university. Under the agreement, IonQ will deliver its Superion 256-qubit trapped-ion quantum computer for installation at FIU.This contract establishes FIU as IonQ’s flagship academic partner in Florida, creating a central hub for quantum research and education across the regio

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Together with more than 20,000 Associates nationwide, AutoNation, Inc. (NYSE:AN) celebrates a decade of DRV PNK and more than $50 million raised and donated to drive out cancer. To commemorate these milestones, AutoNation announced an additional $1 million investment through 10 grants of $100,000 each to 10 longtime partners advancing cancer research and supporting patients, survivors, and caregivers. Over the past decade, DRV PNK has evolved into a defin

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience, Inc. ("Catalyst"), a private medical technology company elevating shoulder arthroplasty through surgeon-focused innovation, today announced it has become the founding partner for shoulder with Redefine Surgery. Building on Catalyst’s leadership in efficient, outcomes-focused shoulder replacement, the partnership expands Catalyst’s role in shaping how shoulder replacement is measured, optimized and continuously improved, unlocking new levels

TAMPA, Fla. & SAN FRANCISCO--(BUSINESS WIRE)--ApalyRx, the pharmacy technology platform that assesses every prescription in real time and routes it to its lowest-cost fulfillment channel on benefit, today announced a partnership with Vida Health, a leading digital health company delivering integrated, longitudinal cardiometabolic and behavioral health care. Together, ApalyRx and Vida Health are enabling self-funded employers to provide plan members with comprehensive clinical weight-loss care a

FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Polaris Rx, a leading provider of long-term care, specialty, and infusion pharmacy solutions, has once again been selected as the exclusive U.S. distributor for FluMist® Home, AstraZeneca's at-home flu vaccine service, available for the 2026-2027 flu season. This marks the second consecutive year Polaris Rx has earned this exclusive distinction. Through FluMist Home, individuals can order FluMist online to be delivered directly to their home without a doc

CORAL SPRINGS, Fla.--(BUSINESS WIRE)--ACIC Equipment USA Inc. is pleased to announce the appointment of Patrice Pelletier as President. In this role, Patrice will lead ACIC Equipment's sales strategy and commercial execution across North America, while also driving the strategic development of a new US facility for the company. Patrice brings more than 20 years of executive leadership experience across industrial technology, infrastructure, and energy transition, with a track record of scaling

ORLANDO, Fla.--(BUSINESS WIRE)-- #InterbodyFusion--Xenix Medical Announces FDA Clearance of the Riva® Anchor Spinopelvic Fixation System with NanoACTIV™ Surface Technology

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) today noted that data from the Phase III HARMONi-GI1 trial, conducted in China and sponsored by Akeso, Inc., featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab, will be featured as part of the Presidential Symposium II at the European Society for Medical Oncology 2026 Congress (ESMO 2026) which takes place October 23–27, 2026, in Madrid, Spain. The presentation will take place on Sunday, O

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #Cordis--Cordis, a global leader in interventional cardiovascular and endovascular technologies, today announced that the U.S. Food and Drug Administration (FDA) has approved the SELUTION SLR™ (Sustained Limus Release) Drug-Eluting Balloon (DEB) for the treatment of coronary in-stent restenosis (ISR), marking a major milestone in expanding treatment options for one of the most complex challenges in interventional cardiology. Physicians now have immediate access to the

BOCA RATON, Fla.--(BUSINESS WIRE)--US healthtech company Massive Bio has appointed international business development consultancy Intralink to support its expansion into South Korea and build partnerships across the country's oncology sector. Massive Bio provides an AI-powered platform that connects cancer patients with suitable clinical trials. The company works with global pharmaceutical companies, hospitals and oncologists to identify patients who meet the often highly specific requirements

MIAMI & PHILADELPHIA--(BUSINESS WIRE)--OpenEvidence, the most widely used medical AI and clinical decision-making tool among U.S. physicians, and Penn Medicine today announced a global partnership to bring AI-powered clinical decision support to Penn Medicine's more than 10,000 clinicians across its seven-hospital U.S. health system. That clinical decision support will also extend to low and middle income countries through the Botswana-UPenn Partnership (BUP). Building on Penn Medicine’s deep c

AGOURA HILLS, Calif.--(BUSINESS WIRE)-- #A2B395--A2 Biotherapeutics to Announce Findings from DENALI-1 Study of A2B395 at 2026 Cell Coast Conference

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a late-stage biopharmaceutical company developing a new class of therapeutics designed to repair helical collagen for the treatment of eye diseases, today announced that Eric Schlumpf, President and CEO of Stuart Therapeutics, will participate in a fireside chat discussion at the Citizens Private Ophthalmology Summit on Thursday, September 17, 2026, at 2 p.m. EDT. The Summit will showcase innovation in ophthalmology with prese

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (Nasdaq: SMMT) announced that updated overall survival (OS) results from the global Phase III HARMONi clinical trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab were presented today at the International Association for the Study of Lung Cancer (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea. As Summit previously announced on July 22, 2026, ivonescimab plus plat

FERNANDINA BEACH, Fla.--(BUSINESS WIRE)-- #KnowLpa--The Family Heart Foundation, a leading research, education and advocacy organization, today announced the publication of a new peer-reviewed study in JACC: Advances demonstrating how its FIND Lp(a)® Machine Learning Model can identify people with atherosclerotic cardiovascular disease (ASCVD) who are more likely to have high lipoprotein(a) — or Lp(a). The model has already been successfully deployed at five large U.S. healthcare systems participating in

SCHAUMBURG, Ill.--(BUSINESS WIRE)--Perdoceo Education Corporation Signs Definitive Agreement to Acquire South University

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced that updated data, including overall survival (OS), from the randomized, double-blind Phase III HARMONi-2 trial featuring the novel, potential first-in-class investigational bispecific antibody ivonescimab is being presented at the International Association for the Study of Lung Cancer’s (IASLC) 2026 World Conference on Lung Cancer (WCLC 2026) in Seoul, Republic of Korea. The HARMON

MIAMI & OTTAWA, Ontario--(BUSINESS WIRE)-- #Canada--OpenEvidence and the Medical Identification Number for Canada Corporation (MINC#NIMC) today announced a partnership to streamline physician verification for Canada and support continued free access for verified Canadian clinicians. Medical knowledge keeps accelerating, and clinicians do not have time to chase down answers across dozens of tabs and paywalls. This partnership reduces friction at the moment of sign-up by allowing Canadian physicians to ver

SARASOTA, Fla.--(BUSINESS WIRE)--Belenos Biosciences, Inc. (“Belenos”), a clinical-stage biotechnology company developing long-acting bispecific antibodies for chronic inflammatory diseases, today announced positive interim results from its ongoing randomized, double-blind, placebo-controlled Phase 1b study of BEL512, an investigational long-acting bispecific antibody targeting thymic stromal lymphopoietin (“TSLP”) and interleukin-13 (“IL-13”), in patients with mild-moderate asthma. Phase 1b Tr

BOCA RATON, Fla.--(BUSINESS WIRE)--Massive Bio, Inc., a global leader in AI-driven precision oncology and clinical trial matching, and PrecisCa, an oncology practice support platform offering evidence-based treatment guidance, clinical trial matching, patient communications, and expert second opinions, today announced a strategic partnership to expand cancer patient access to clinical trials across the United States. Under the agreement, Massive Bio will provide concierge support, reporting, an

NAPLES, Fla.--(BUSINESS WIRE)--Catalyst OrthoScience Inc. (“Catalyst”), a private medical device technology company redefining shoulder arthroplasty through simplified, surgeon-focused innovation, today announced that it has entered into a settlement agreement with Shoulder Innovations, Inc. (“Shoulder Innovations”) to resolve all pending patent litigation between the two companies. The agreement resolves the dispute in its entirety. The terms of the settlement agreement are confidential. “Inte

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. (“Starfighters” or the “Company”) (NYSE American: FJET), the space company operating the world’s only commercial fleet of flight-ready Mach 2+ supersonic aircraft, and Vaya Defense & Space, Inc. (“Vaya”), a privately held developer of the patented Vortex-Hybrid rocket engine, today announced entering into a memorandum of understanding (MOU) to explore collaboration on supersonic captive-carry flight testing and air-launch

MIAMI--(BUSINESS WIRE)--Lotus Neuro, a clinical-stage biotechnology company pairing focused ultrasound with leading therapeutic modalities to treat focal neurologic disease, today announced its public launch. Spun out in December 2025 from Insightec, the global leader in incisionless focused ultrasound, Lotus Neuro is built on a clinically validated platform for precision modulation of the blood-brain barrier (BBB) and is dedicated to solving the delivery problem that has stalled decades of pro

MIAMI--(BUSINESS WIRE)--DermaSensor Inc., a leader in AI-powered skin cancer diagnostic technology, announced today the close of a $4M Series B extension, including institutional and strategic investors, alongside the launch of a community investment round on Wefunder. This new community financing has already raised more than $1 million at the same terms as the $4M. This follows the company’s $16M Series B, closed in 2025, and brings the total investment in the company to $48 million. The commu

MIAMI--(BUSINESS WIRE)-- #Glaucoma--Heru announced the U.S. launch of the new PretestPro on its Heru Prime wearable platform. PretestPro runs four pretest exams in just 90 seconds.

ATLANTIC BEACH, Fla.--(BUSINESS WIRE)--nPhase launches nPhase.ai and its agentic SCE, turning raw clinical trial data into submission-ready CDISC outputs 4x faster with 80% fewer resources.

LAKE FOREST, Calif.--(BUSINESS WIRE)--SinglePass, Inc., developer of the SinglePass biopsy closure device, today announced the publication of a multicenter (Hoag Health System, Newport Beach and Irvine, California) retrospective clinical data study in the Journal of Vascular and Interventional Radiology (JVIR). Across 120 consecutive patients followed for 30 days, the SinglePass device achieved a 100% technical success rate with zero clinically significant bleeding events.1 Percutaneous biopsy

MONTPELLIER, France & MIAMI--(BUSINESS WIRE)--Precision IO Group, the parent company of NeuWave Medical and Quantum Surgical, will unveil new features for its Epione® robotic platform at the 2026 annual congress of the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) in Copenhagen, Denmark, September 5–9, on Booth D39. The updated platform will feature new AI capabilities and compatibility with one of the latest-generation angiography systems from GE HealthCare enabling

MIAMI--(BUSINESS WIRE)---- $SMMT--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive overall survival (OS) results from the randomized, double-blind Phase III HARMONi-2 study evaluating ivonescimab monotherapy against pembrolizumab monotherapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) whose tumors have positive PD-L1 expression. HARMONi-2 (AK112-303) is a single-region, multi-center Phase III study conducted in China

MIAMI--(BUSINESS WIRE)--Over 90 Segal Trials employees have joined CISCRP’s 8th Annual Medical Heroes Appreci-A-Thon, a two-week event combining physical activity and fundraising to recognize the clinical research participants and professionals who make medical progress possible. Running September 1 through September 15, the Appreci-A-Thon raises funds to support CISCRP’s work educating and empowering patients and the public about clinical research. Just two days into the challenge, Segal Trial

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ supersonic aircraft, today announced it has signed a memorandum of understanding (“MOU”) with The Bionetics Corporation (“Bionetics”) to integrate and process a series of pathfinder small payloads for missions aboard the Company’s F-104 aircraft. Under the MOU, Bionetics will work with

MIAMI--(BUSINESS WIRE)-- #DebtJustice--AIDS Healthcare Foundation (AHF), in collaboration with the University of Miami Public Health Policy Lab, will co-host a webinar, “Freedom from Debt: A Global Dialogue on Fiscal Space, Health, and Development,” on Thursday, September 3, 2026, at 10:00 AM EDT, virtually via Zoom. Register here. Sovereign debt has emerged as a defining challenge at the intersection of global finance, sustainable development, and public health. Across many low- and middle-income countries,

KENNEDY SPACE CENTER, Fla.--(BUSINESS WIRE)--Starfighters Space, Inc. ("Starfighters" or the "Company") (NYSE American: FJET), the space company operating the world's only commercial fleet of flight-ready Mach 2+ F-104 supersonic aircraft, announced it will participate in the September 12-13 AIRSHO at the Midland International Air & Space Port in Texas, showcasing its historic F-104 aircraft in both flight and static displays. For Starfighters, the event provides a unique opportunity to sho

MIAMI--(BUSINESS WIRE)--DermaSensor Inc., a leader in AI-powered skin cancer diagnostic technology, today announced a major expansion of its U.S. commercial strategy through a series of strategic partnerships to accelerate adoption of its FDA cleared, handheld skin cancer detection device across primary care, enterprise healthcare, and federal healthcare systems. The Company's commercial expansion includes 1) an approved supplier relationship with Henry Schein, Inc., the world’s largest provide

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics will participate in the Morgan Stanley 24th Annual Global Healthcare Conference, Sept. 14–16, 2026, in New York.

MIAMI & LEAWOOD, Kan.--(BUSINESS WIRE)-- #clinicalai--The American Medical Society for Sports Medicine (AMSSM) and OpenEvidence today announced a partnership that will focus on co-developing AI-powered educational resources on sports medicine for both patients and clinicians. This exclusive collaboration brings the expertise of AMSSM’s sports medicine physicians to OpenEvidence, the leading AI-powered clinical decision support platform, and will build on the AMSSM’s robust foundation of educational materials.

FORT MYERS, Fla.--(BUSINESS WIRE)--NeoGenomics announced expanded MolDX coverage for its RaDaR® ST MRD assay for immunotherapy monitoring in late-stage solid tumors.

LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced its participation in the Wells Fargo 21st Annual Healthcare Conference, which is being held September 8-10, 2026 at the Encore Boston Harbor in Everett, MA. Management will participate in a fireside chat on Wednesday, September 9th at 1:30 p.m. Eastern Time. A live audio webcast of the fireside chat will be accessible under the “Events” section of the company’s investor relations website: https://www.conmed.com/en/inv

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a late-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of Dave LeCause as senior commercial advisor. LeCause will lead the company's commercial strategy as Stuart advances its lead therapeutic candidate, ST-100 for dry eye disease. ST-100 is expected to begin Phase 3b clinical trials in the first quarter of 2027. LeCause joins Stu

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that its partner Akeso Inc. announced positive topline results from the randomized Phase III HARMONi-GI1 study (AK112-309) evaluating ivonescimab plus chemotherapy compared with durvalumab plus chemotherapy as a first-line treatment for patients with advanced biliary tract cancer (BTC). HARMONi-GI1 is a single-region, multi-center, Phase III study conducted in China and sponsored by Akeso, with all relevant data exclusi

TAMPA, Fla.--(BUSINESS WIRE)--Catalent has completed a significant debt refinancing transaction to support its future growth while reducing its annual interest expenses.

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. In HARMONi, ivonescimab in combination with platinum-doublet chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to placebo plus platinum-doublet chemotherapy in patients with epidermal growth factor receptor (EGFR)-mu

MIAMI LAKES, Fla.--(BUSINESS WIRE)-- #ClinicalResearch--Segal Trials today announced its participation in the Phase 2 ZEPHYR clinical trial evaluating MapLight Therapeutics’ investigational muscarinic receptor-targeted therapy, ML-007C-MA, for the treatment of adults experiencing an acute exacerbation of schizophrenia.MapLight Therapeutics recently announced topline results from the multicenter Phase 2 study. Segal Trials is proud to have contributed to this important clinical development program and congratulates

MIAMI--(BUSINESS WIRE)-- #AI--Arcadia Capital, the premier strategic advisor and investment bank to leaders in the tech and tech services ecosystem, served as exclusive financial advisor to InformedDNA ("IDNA" or "the Company"), a portfolio company of Truehelm and QHP Capital, in the divestiture of its Genetic Testing Utilization Management ("GTUM") business unit to Zyter, a subsidiary of Infinite, a global technology company. The transaction marks the Company's continued investment in and focus on D

TAMPA, Fla.--(BUSINESS WIRE)--Smart Meter, a leading provider of cellular-connected remote patient monitoring (RPM) solutions, today called on RPM vendors, healthcare providers, and industry partners to mobilize against provisions in the Centers for Medicare & Medicaid Services' (CMS) proposed Calendar Year 2027 Physician Fee Schedule (PFS) that could sharply curtail access to remote monitoring for millions of Medicare beneficiaries. The proposed rule, issued July 14, 2026, includes several

MINNETONKA, Minn. & REHOVOT, Israel & ORLANDO, Fla.--(BUSINESS WIRE)--Stratasys Ltd. (NASDAQ: SSYS), a global leader in additive manufacturing solutions, and Limbitless Solutions, a nonprofit research facility at the University of Central Florida dedicated to empowering children through bionics, today announced the expansion of a 12-year collaboration that has already helped deliver hundreds of 3D-printed prosthetic devices to children across the United States and beyond. The expanded partnersh

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a clinical-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of David Jakeman as chief financial officer. Jakeman will lead the company's finance and accounting operations as Stuart advances its lead candidate, ST-100 for dry eye disease, through completion of its pending Phase 3b clinical trial and into preparations for commerciali

PALM BEACH GARDENS, Fla.--(BUSINESS WIRE)--Wellvii today announced that its innovative BP Go blood pressure monitoring technology achieved FDA clearance, marking a significant milestone in the company’s mission to transform remote patient monitoring and connected healthcare. The BP Go is designed to simplify the blood pressure measurement by utilizing a convenient finger-based measurement approach, eliminating many of the challenges associated with traditional arm cuffs. The device is designed

BOCA RATON, Fla.--(BUSINESS WIRE)--Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company committed to providing highly effective, non-invasive treatments for oncological and non-oncological skin conditions, today announced financial results and business highlights for the three months ended June 30, 2026. Highlights included: Revenues of $2.3 million for the quarter ended June 30, 2026, a decrease of $5.0 million, from the 2025 quarter. The decrease was driven by a lower number of un

BOCA RATON, Fla.--(BUSINESS WIRE)-- #HealthcareInnovation--SurGenTec®, a developer of surgical technologies for spine and orthopedic procedures, today announced that it has been named to the 2026 Inc. 5000, the annual list of the fastest-growing private companies in America. The prestigious list recognizes companies that have achieved remarkable growth while driving innovation, creating jobs, and shaping the future of the economy. Companies on the 2026 Inc. 5000 are ranked according to percentage revenue growth from 2

HOLLYWOOD, Fla. & DALLAS--(BUSINESS WIRE)--DermCare Management, LLC (“DermCare”), a leader in specialized dermatology and cosmetic surgery practice-management services, and U.S. Dermatology Partners (“USDP”), a leading dermatology practice, today announced the completion of a strategic transaction that creates one of the largest dermatology groups in the U.S., spanning 12 states. The transaction unites two clinically focused organizations with aligned missions to expand access to high-quality d

MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) today noted that, on August 12, 2026, its partner Akeso Inc. (Akeso, HKEX Code: 9926.HK) announced receipt of marketing authorization in China from the National Medical Products Administration (NMPA) for the use of ivonescimab, a novel, potential first-in-class investigational bispecific antibody, in combination with chemotherapy for the first-line treatment of patients with advanced squamous non-small cell lung cancer (NSCLC). Thi

BOCA RATON, Fla.--(BUSINESS WIRE)--TherapeuticsMD, Inc. (“TherapeuticsMD” or the “Company”) (NASDAQ: TXMD), a company that owns rights to pharmaceutical royalties, today reported financial results for the three months ended June 30, 2026. Second Quarter 2026 Financial Results Net Income from Continuing Operations Net income from continuing operations totaled $164 thousand, compared to net income of $545 thousand for the second quarter of 2025. License Revenues from Continuing Operations The Com

SARASOTA, Fla.--(BUSINESS WIRE)--Belenos Biosciences Announces Positive CRSwNP Results

TAMPA, Fla.--(BUSINESS WIRE)--American Ocean Minerals Corporation ("AOMC" or the "Company") today announced that Paul Warmé has been appointed Chief Financial Officer. Through its previously announced merger with Odyssey Marine Exploration (NASDAQ: OMEX), AOMC is establishing a U.S.-based global supply chain for critical minerals and rare earth elements sourced from deep-sea polymetallic nodules, and Warmé’s appointment further strengthens the executive leadership team as the Company advances t

WESTON, Fla.--(BUSINESS WIRE)--ILiAD Biotechnologies, Inc. (ILiAD), an advanced clinical stage biotech company focused on the prevention and treatment of disease caused by Bordetella pertussis, today announced the appointments of Jim Wassil, currently Chief Operating Officer at Vaxcyte; Suha Jhaveri, former Strategic Advisor at Cidara before its acquisition by Merck; and Bill Warren, former Global Head of Antigen Design at Sanofi Vaccines, as independent members of ILiAD’s Board of Directors. T

CLEARWATER, Fla.--(BUSINESS WIRE)--PriceMDs and Leaf Health today announced the integration of PriceMDs’ API into LeafIQ, Leaf Health’s pharmacy analytics and reporting platform. The integration enables brokers and third-party administrators to evaluate applicable SourceDirectRx pricing and initiate clinical referrals while analyzing pharmacy spend and specialty medication exposure. Within LeafIQ, users can compare a plan’s current medication cost with available SourceDirectRx pricing without l

GAITHERSBURG, Md.--(BUSINESS WIRE)--Silvec Biologics Inc., a Maryland-based agricultural biotechnology company, is pleased to announce that its novel RNA-based therapy delivery product is now registered for unconditional commercial use under the U.S. Environmental Protection Agency’s (EPA) Federal Insecticide, Fungicide and Rodenticide Act. The product is based on a naturally non-transmitted version of the citrus tristeza virus that is already found in most Florida citrus trees that has been re